Propel Mini

Propel Mini Uses, Dosage, Side Effects, Food Interaction and all others data.

Propel Mini is a corticosteroid demonstrating anti-inflammatory properties. The precise mechanism of corticosteroids action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.

Propel Mini is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Propel Mini has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.

Propel Mini
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Propel Mini
Availability	Prescription only
Generic	Mometasone
Mometasone Other Names	Mometason, Mometasona, Mométasone, Mometasone, Mometasonum
Related Drugs	Dupixent, Xolair, ProAir Digihaler, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA
Weight	1350mcg, 370mcg, 50mcg/inh
Type	Nasal implant, nasal spray
Formula	C₂₂H₂₈Cl₂O₄
Weight	Average: 427.361 Monoisotopic: 426.136464798
Protein binding	98% to 99% (in a concentration range of 5 to 500 ng/mL).
Groups	Experimental
Therapeutic Class	Other Topical corticosteroids
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Propel Mini cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses, such as psoriasis and atopic dermatitis.

Propel Mini is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Asthma, Bacterial Sinusitis, Dermatitis, Pruritus, Sinusitis

How Propel Mini works

Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Propel Mini furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.

Dosage

Propel Mini dosage

A thin film of Propel Mini Furoate cream should be applied to the affected skin areas once daily.Safety and effectiveness in paediatric patients below 2 years of age have not been established.

Side Effects

Propel Mini Furoate cream is generally well tolerated. Burning, Pruritus and skin atrophy may occur.

Toxicity

The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.